SLS is down 17.33% today. Volume is 18.55M vs a 30-day average of 5.71M (3.25x).
SELLAS Life Sciences Group, Inc is scheduled to report earnings Tue, Nov 10, 2026. Analysts expect EPS of $-0.05. Stocks often move sharply on earnings day.
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapi…
Sellas Life Sciences remains a 'Strong Sell,' as the REGAL trial delay signals increased risk of failure and diminished probability of success. Learn more about SLS stock here.
Sellas Life Sciences is a late-stage biotech with no product sales, hinging on its Phase 3 REGAL trial for GPS in AML. Click to know why I rate SLS stock a Hold.
Executive severance changes from June and Sellas’ sizable ASH conference booth have fueled deal speculation.
Stergiou said SELLAS was entering its “next chapter” with GPS and SLS009 but did not disclose a clinical trial timeline or confirm an upcoming announcement.